Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG OUTCOME (#60)

4:30 PM

Michael d'Emden

ADS Clinical Orals - Type 2 Therapies

Effect of Empagliflozin on Nephropathy in Subgroups by Age: Results from EMPA-REG OUTCOME (#33)

11:45 AM

Michael d'Emden

ADS Clinical Orals - Renal & Foot Complications

Prevalence and independent factors associated with diabetes-related and non-diabetes-related foot ulcers in a representative inpatient population (#323)

2:00 PM

Peter Lazzarini

ADS Clinical Poster Session - Diabetes Complications - Diabetic Foot

Switching from twice-daily basal insulin to once-daily new insulin glargine 300 U/mL (Gla-300): an analysis in people with T2DM (EDITION 1 and 2) (#256)

2:00 PM

Michael d'Emden

ADS Clinical Poster Session - Therapy of type 2 diabetes

Evaluation of fasting blood glucose as an initial diagnostic test for gestational diabetes mellitus (GDM). (#135)

3:45 PM

Michael d'Emden

ADS Clinical Orals - Pregnancy, diet & exercise

Fenofibrate Reduces Uric Acid Levels and Gout Events in Type 2 Diabetes: Results from the Field Study (#63)

5:15 PM

Boris Waldman

ADS Clinical Orals - Type 2 Therapies